The mandatory Phase 1 clinical trial in healthy volunteers in China precedes the inclusion of Chinese clinical sites by late 2026 into the single Global Phase 3 registration trial of BV100 in ...

The aggregate gross proceeds to Benitec from the underwritten public offering and the concurrent registered direct offering are expected to be approximately $100 million, prior to deducting ...

Strong RUCONEST® growth continued in the third quarter of 2025, with revenue of US$82.2 million, a 29% increase compared to the third quarter of 2024. Revenue for the first nine months of 2025 was ...

Le CBD pourrait favoriser un meilleur sommeil en agissant sur le stress et l’endormissement. Découvrez ses effets, le bon ...

BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial ...

J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers for the offering. Stifel, Wells Fargo Securities and BTIG are also acting as book-running managers for ...

Gross profit for the third quarter of 2025 was $24.2 million or 80% of revenue, a decrease of $1.0 million compared to gross profit of $25.2 million or 71% of revenue for the third quarter of 2024.

Conference Call and Webcast scheduled for tomorrow, November 6, 2025 at 10:00 am MT. EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the pa ...

IMCIVREE est désormais remboursé pour le cadre de la gestion du poids chez les patients atteints du syndrome de Bardet-Biedl (BBS) en Ontario, en Alberta, en Colombie-Britannique, en Saskatchewan, en ...

The live webcasts and archives of these fireside chats can also be accessed on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website.

GAAP net loss for the third quarter of 2025 was $38.0 million, compared to $60.7 million for the third quarter of 2024. Non-GAAP net loss for the third quarter of 2025 was $36.8 million, compared to ...

Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024. The decrease of $2.6 ...